It is estimated that as many as 58 million people suffer from hepatitis C worldwide. The World Health Organization estimates that roughly 1.1 million deaths occurred in 2019 due to hepatitis B and C, and their effects include ‘liver cancer, cirrhosis, and other conditions caused by chronic viral hepatitis.’
Paris, France: Cannabis use is inversely associated with obesity in patients with chronic hepatitis C virus (HCV) infection, according to data published in the Journal of Cannabis Research.
A team of French researchers assessed the relationship between lifetime cannabis use and obesity in a cohort of over 6,300 HCV patients.
Authors reported, “[F]ormer and, to a greater extent, current cannabis use were consistently associated with smaller waist circumference, lower BMI, and lower risks of overweight, obesity, and central obesity in patients with chronic HCV infection. … To our knowledge, this is the first time that such associations have been highlighted for HCV-infected patients.”
The study’s findings are consistent with those of analyses of other cohorts – such as those here, here, and here - reporting that marijuana use is typically associated with lower BMI and with lower rates of obesity.
Full text of the study, “Cannabis use as a factor of lower corpulence in hepatitis C-infected patients: Results from the ANRS C022 Hepather cohort,” is available in the Journal of Cannabis Research. Additional information on cannabis and HCV is available from NORML.
Share article
